{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T16:12:23Z","timestamp":1760890343125,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasis is a skin inflammatory condition for which significant progress has been made in its management by the use of targeted biological drugs. Detection of latent <jats:italic>M. tuberculosis<\/jats:italic> infection (LTBI) is mandatory before starting biotherapy that is associated with reactivation risk. Together with evaluation of TB risk factors and chest radiographs, tuberculin skin tests (TST) and\/or blood interferon-\u03b3-release assays (IGRA), like the QuantiFERON (QFT), are usually performed to diagnose <jats:italic>M. tuberculosis<\/jats:italic> infection. Using this approach, 14\/49 psoriatic patients prospectively included in this study were identified as LTBI (14 TST<jats:sup>+<\/jats:sup>, induration size \u2265 10mm, 8 QFT<jats:sup>+<\/jats:sup>), and 7\/14 received prophylactic anti-TB treatment, the other 7 reporting past-treatment. As the specificity and sensitivity of these tests were challenged, we evaluated the added value of an IGRA in response to a mycobacterial antigen associated with latency, the heparin-binding haemagglutinin (HBHA). All but one TST<jats:sup>+<\/jats:sup> patient had a positive HBHA-IGRA, indicating higher sensitivity than the QFT. The HBHA-IGRA was also positive for 12\/35 TST<jats:sup>-<\/jats:sup>QFT<jats:sup>-<\/jats:sup> patients. Measurement for 15 psoriatic patients (12 with HBHA-IGRA<jats:sup>+<\/jats:sup>) of 8 chemokines in addition to IFN-\u03b3 revealed a broad array of HBHA-induced chemokines for TST<jats:sup>+<\/jats:sup>QFT<jats:sup>-<\/jats:sup> and TST<jats:sup>-<\/jats:sup>QFT<jats:sup>-<\/jats:sup> patients, compared to a more restricted pattern for TST<jats:sup>+<\/jats:sup>QFT<jats:sup>+<\/jats:sup> patients. This allowed us to define subgroups within psoriatic patients characterized by different immune responses to <jats:italic>M. tuberculosis<\/jats:italic> antigens that may be associated to different risk levels of reactivation of the infection. This approach may help in prioritizing patients who should receive prophylactic anti-TB treatment before starting biotherapies in order to reduce their number.<\/jats:p>","DOI":"10.3389\/fimmu.2021.672894","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T19:09:02Z","timestamp":1622747342000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Tuberculosis Risk Stratification of Psoriatic Patients Before Anti-TNF-\u03b1 Treatment"],"prefix":"10.3389","volume":"12","author":[{"given":"Farida","family":"Benhadou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violette","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Domont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Willaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Van Praet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Locht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Mascart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Corbi\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339","article-title":"Identification and Management of Associated ComorbidiTy (IMPACT) Project Team: Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest. Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/abd1806-4841.20153038","article-title":"Psoriasis: Classical and Emerging Comorbidities","volume":"90","author":"Oliveira Mde","year":"2015","journal-title":"An Bras Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1076793","article-title":"An Overview of Developing TNF-alpha Targeted Therapy for the Treatment of Psoriasis","volume":"24","author":"Campa","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3899\/jrheum.140104","article-title":"Tuberculosis Reactivation Risk in Dermatology","volume":"91","author":"Petiscelli","year":"2014","journal-title":"J Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e012567","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of Tuberculosis in Patients Treated With TNF-alpha Antagonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and Safety of Guselkumab, an anti-interleukin-23 Monoclonal Antibody, Compared With Adalimumab for the Continuous Treatment of Patients With Moderate to Severe Psoriasis: Results From the Phase III, Double-Blinded, Placebo- and Active Comparator-Controlled VOYAGE 1 Trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.153","article-title":"Efficacy and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through 108 Weeks of a Randomized, Controlled Phase 3 Clinical Trial (UNCOVER-3)","volume":"77","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(04)01206-X","article-title":"Interferon-\u03b3 Assays in the Immunodiagnosis of Tuberculosis: A Systematic Review","volume":"4","author":"Pai","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nri.2017.69","article-title":"Flynn JL : Heterogeneity in Tuberculosis","volume":"17","author":"Cadena","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of Latent Mycobacterium Tuberculosis Infection: WHO Guidelines for Low Tuberculosis Burden Countries","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur Respir J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clim.2007.08.012","article-title":"Tnfalpha Blockade in Human Diseases: An Overview of Efficacy and Safety","volume":"126","author":"Lin","year":"2008","journal-title":"Clin Immunol"},{"key":"B13","article-title":"False-Positive Tuberculin Skin Tests: What is the Absolute Effect of BCG and non-Tuberculous Mycobacteria","volume":"10","author":"Farhat","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0188631","DOI":"10.1371\/journal.pone.0188631","article-title":"Mcbryde ES : Interferon-gamma Release Assay for the Diagnosis of Latent Tuberculosis Infection: A Latent-Class Analysis","volume":"12","author":"Doan","year":"2017","journal-title":"PloS One"},{"key":"B15","article-title":"Patakas D: Tuberculosis in Patients Receiving anti-TNF Agents Despite Chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2014.938691","article-title":"Diagnosis of Latent Tuberculosis Infection Before Initiation of Anti-Tumor Necrosis Factor Therapy Using Both Tuberculin Skin Test and QuantiFERON-TB Gold In Tube Assay","volume":"46","author":"Kim","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.05.006","article-title":"Equal Sensitivity of the New Generation QuantiFERON-TB Gold Plus in Direct Comparison With the Previous Test Version QuantiFERON-TB Gold IT","volume":"22","author":"Hoffmann","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e926","DOI":"10.1371\/journal.pone.0000926","article-title":"Heparin-Binding-Hemagglutinin-Induced IFN-gamma Release as a Diagnostic Tool for Latent Tuberculosis","volume":"2","author":"Hougardy","year":"2007","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00651-13","article-title":"Key Role of Effector Memory CD4+ T Lymphocytes in a Short-Incubation Heparin-Binding Hemagglutinin Gamma Interferon Release Assay for the Detection of Latent Tuberculosis","volume":"21","author":"Wyndham-Thomas","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1084\/jem.184.3.993","article-title":"Identification of a Heparin-Binding Hemagglutinin Present in Mycobacteria","volume":"184","author":"Menozzi","year":"1996","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1086\/338833","article-title":"Differential T and B Cell Responses Against Mycobacterium Tuberculosis Heparin-Binding Heamgglutinin Adhesin in Infected Healthy Individuals and Patients With Tuberculosis","volume":"185","author":"Masungi","year":"2002","journal-title":"J Inf Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e43285","DOI":"10.1371\/journal.pone.0043285","article-title":"Risk Stratification of Latent Tuberculosis Defined by Combined Interferon Gamma Release Assays","volume":"7","author":"Corbi\u00e8re","year":"2012","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1106","article-title":"Patients With Psoriasis are More Likely to be Treated for Latent Tuberculosis Infection Prior to Biologics Than Patients With Inflammatory Bowel Disease","volume":"91","author":"Bassukas","year":"2011","journal-title":"Acta Derm Venereol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12011","article-title":"Latent Tuberculosis Infection and Active Tuberculosis in Patients With Psoriasis: A Study on the Incidence of Tuberculosis and the Prevalence of Latent Tuberculosis Disease in Patients With Moderate-Severe Psoriasis in Spain. BIOBADADERM Registry","volume":"27","author":"Sanchez-Moya","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2133.2009.09331","article-title":"Tuberculosis Screening in Patients With Psoriasis Before Antitumour Necrosis Factor Therapy: Comparison of an Interferon-Gamma Release Assay vs. Tuberculin Skin Test","volume":"161","author":"Laffitte","year":"2009","journal-title":"Br J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00016611","article-title":"Diagnosis of Tuberculosis in Patients With Psoriasis: The Need for a Modified Approach","volume":"38","author":"Bassukas","year":"2011","journal-title":"Eur Respir J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-97","article-title":"Associations Between Selected Immune-Mediated Diseases and Tuberculosis: Record-Linkage Studies","volume":"11","author":"Ramagopalan","year":"2013","journal-title":"BMC Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ni1449","article-title":"Il-23 and IL-17 in the Establishment of Protective Pulmonary CD4+ T Cell Responses After Vaccination and During Mycobacterium Tuberculosis Challenge","volume":"8","author":"Khader","year":"2007","journal-title":"Nat Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nm1090","article-title":"Methylation-Dependent T Cell Immunity to Mycobacterium Tuberculosis Heparin-Binding Hemagglutinin","volume":"10","author":"Temmerman","year":"2004","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.12.6799-6805.2004","article-title":"The Mycobacterial Heparin-Binding Hemagglutinin is a Protective Antigen in the Mouse Aerosol Challenge Model of Tuberculosis","volume":"72","author":"Parra","year":"2004","journal-title":"Infect Immun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.02.008","article-title":"Regulatory T-cell Subsets in Response to Specific Mycobacterium Tuberculosis Antigens In Vitro Distinguish Among Individuals With Different QFT and TST Reactivity","volume":"157","author":"Serrano","year":"2015","journal-title":"Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200701-084OC","article-title":"Regulatory T Cells Depress Immune Responses to Protective Antigens in Active Tuberculosis","volume":"176","author":"Hougardy","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-018-00576-4","article-title":"Diagnostic Performance in Active TB of QFT-Plus Assay and Co-Expression of CD25\/CD134 in Response to New Antigens of Mycobacterium Tuberculosis","volume":"208","author":"Sauzullo","year":"2019","journal-title":"Med Microbiol Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-6-55","article-title":"Purification of Native HBHA From Mycobacterium Avium Subsp. Paratuberculosis","volume":"6","author":"Lefrancois","year":"2013","journal-title":"BMC Res Notes"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901214","article-title":"Natural T Cell Epitope Containing Methyl Lysines on Mycobacterial Heparin-Binding Hemagglutinin","volume":"204","author":"Corbi\u00e8re","year":"2020","journal-title":"J Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.chom.2017.12.010","article-title":"Bcg Vaccination Protects Against Experimental Viral Infection in Humans Through the Induction of Cytokines Associated With Trained Immunity","volume":"23","author":"Arts","year":"2018","journal-title":"Cell Host Microbe"},{"key":"B37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/imr.12617","article-title":"The Role of the Interleukin-1 Family in Trained Immunity","volume":"281","author":"Moorlag","year":"2018","journal-title":"Immunol Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.672894\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T19:09:06Z","timestamp":1622747346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.672894\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2021.672894"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.672894","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"article-number":"672894"}}